Roche study shows benefits of Tecentriq/Avastin in treating kidney cancer

Roche has announced new clinical trial data showing the benefits of a new Tecentriq-based treatment regimen for advanced kidney cancer.

Results from the phase III IMmotion151 study showed that the combination of Tecentriq and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death among people with advanced or metastatic renal cell carcinoma.

The new regimen met its co-primary endpoint of superior progression-free survival, compared with sunitinib, among patients whose disease expressed the PD-L1 protein.

IMmotion151 is the second successive positive phase III study of Tecentriq plus Avastin, following the positive findings of the IMpower150 study among non-squamous non-small cell lung cancer patients.

Data from these studies will be used to support future regulatory approvals for this innovative regimen.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "We believe that the regimen of Tecentriq and Avastin may enhance the potential of the immune system in the initial treatment of advanced kidney cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.